Hóa chất Unilosa - Việt Nam

Name: Hóa chất Unilosa - Việt Nam
Address: Singapore, 049422, SG
Telephone: +84913191396

Home
Singapore
Singapore
Hóa chất Unilosa - Việt Nam

Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from Hóa chất Unilosa - Việt Nam, Chemical company, Singapore.

UNILOSA International Pvt Ltd chuyên cung cấp hóa chất cho nhiều ngành công nghiệp như xử lý nước, sản xuất hàng dệt, bột giấy và giấy, chất tẩy rửa, dược phẩm, sơn và chất bao, luyện kim,vv

09/08/2026

🌿 Green chemistry is not a trend - it is now a regulatory requirement. Here is what every chemical buyer must know in 2026.

SSbD = Safe and Sustainable by Design. The new EU framework requiring ALL chemicals to prove safety across their ENTIRE lifecycle - not just when in use.

What SSbD covers:
✅ Environmental impact (production to disposal)
✅ Human health & safety in processing
✅ Social and economic sustainability
✅ Full lifecycle analysis - Cefic framework

THE GREAT DIVERGENCE (McKinsey 2026):
Chemical industry permanently splitting into 2:
🔴 Commodity = competing on cost - high volatility
🟢 Specialty = competing on performance & compliance - lower volatility, stronger returns

WINNERS UNDER GREEN CHEMISTRY:
🌿 Bismuth - replacing toxic lead in pigments & coatings
🌿 Zinc Phosphate - replacing lead-based anti-corrosion primers
🌿 NaHCO3 - replacing harsher pH adjusters in food & pharma
🌿 SLES/LABSA - biodegradable surfactants gaining market share

Unilosa supplies all - REACH compliant, full documentation, Singapore-based.

📩 [email protected] 🌐 www.unilosa.com 📍 Singapore 🇸🇬

References: European Commission, European Chemicals Agency (ECHA), Cefic (European Chemical Industry Council), McKinsey & Company, and published green chemistry research.

05/08/2026

☠️ Forever chemicals are being banned globally. Here is everything the chemical industry must know in 2026.

WHAT ARE PFAS? Approximately 10,000+ synthetic chemicals that do not break down in nature or the human body. Found in non-stick cookware, food packaging, waterproof clothing & firefighting foam.

THE BAN:
🇪🇺 EU: Universal PFAS restriction approaching 2027 - broadest chemical ban in history.
🇺🇸 US: California, New York, Minnesota already restricting PFAS in textiles & packaging.
🇬🇧 UK & Canada: Active restrictions. FDA reviewing PFAS in food contact materials.

THE REPLACEMENT RACE (demand surging approximately 30-50%):
✅ Bismuth compounds - replacing PFAS coatings
✅ Zinc Phosphate - replacing lead & PFAS-based primers
✅ LABSA & SLES - replacing PFAS in cleaning products

Unilosa supplies ALL of these - PFAS-free, REACH compliant, fully documented.

📩 [email protected] 🌐 www.unilosa.com 📍 Singapore 🇸🇬

References: European Chemicals Agency (ECHA), U.S. Environmental Protection Agency (EPA), U.S. Food and Drug Administration (FDA), OECD, and published industry research on PFAS.

01/08/2026

🤖 Chemistry + AI = the most powerful industrial combination in history. Here is what is happening right now in 2026.

AI in SUPPLIER QUALIFICATION: Thousands of AI agents evaluating ESG, financial risk and market intelligence simultaneously. What took weeks now takes minutes.

AI in R&D: Cutting prediction inaccuracy by approximately 50%. Drug timelines from approximately 17 years to approximately 4 years. Formulation discovery accelerating.

AI in PROCUREMENT: Price monitoring, supplier comparison, risk flagging, lead time prediction - all automated. AI performance is now the industry baseline.

AI DATA CENTER DEMAND: New surprise. Data centers need advanced cooling chemicals, ultra-pure gases & semiconductor-grade materials. Industrial production: approximately +2.2% in 2026, approximately +3.2% in 2027.

Companies not using AI in 2026 are falling behind - not standing still.

At Unilosa Chemicals, we track these market shifts daily - supplying specialty chemicals from Singapore.

📩 [email protected] 🌐 www.unilosa.com 📍 Singapore 🇸🇬

References: McKinsey & Company, American Chemistry Council (ACC), Deloitte, and published industry research on AI in chemicals and supply chain.

28/07/2026

🧪 Every breakthrough medicine starts with a high-purity chemical. Unilosa supplies them.

NaHCO3 - PHARMA GRADE: Tablet disintegrant, pH buffer, antacid active. Minimum 99.0-100.5% assay. GLP-1 pill revolution boosting tablet manufacturing demand globally. Unilosa: Tech, Feed, Food & Pharma Grade.

BISMUTH COMPOUNDS: Active in Pepto-Bismol and GI medicines. Eco-friendly non-toxic lead alternative. As GLP-1 drugs create GI side effects in patients, bismuth formulations gain relevance worldwide.

CaCO3 - PHARMA GRADE: Active in calcium supplements & antacid tablets. Also tablet filler, binder & excipient. Obesity revolution boosting GI supplement demand. Unilosa: Industrial, Food, Pharma & Coated Grade.

ERBIUM OXIDE (Er2O3): Critical dopant for Er:YAG surgical lasers - dermatology, ophthalmology, dental. Also used in fiber-optic medical diagnostic amplifiers. As precision cancer diagnosis advances - erbium demand is rising.

The purity of raw materials determines the safety and shelf life of every medicine.

📩 [email protected] 🌐 www.unilosa.com 📍 Singapore 🇸🇬

References: U.S. Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.), U.S. FDA, official manufacturer technical data sheets, and published pharmaceutical research.

23/07/2026

💰 US and Europe are in the biggest drug innovation race in medical history. Here is the scoreboard for 2025-2026.

OBESITY - Approximately $100 billion market. Eli Lilly hit $1 trillion market cap. Oral GLP-1 pill FDA approved December 2025. Oral GLP-1 market: approximately 20% of $80 billion GLP-1 total.

CANCER - Approximately 10 targeted therapies approved in 2025. Record Q1-Q2 2026 approvals. Breakthrough designations for lung, pancreatic & blood cancers simultaneously.

GENE THERAPY - Approximately 9 products approved by FDA in 2024. Ionis RNA drug: approximately $108 million in 2025 sales. First permanent genetic cures are commercially real.

AI IN DRUG DISCOVERY - Compressing approximately 17-year timelines to approximately 4 years. Industrial production: approximately +2.2% in 2026, approximately +3.2% in 2027.

Every drug on every frontier starts with pharma-grade chemical raw materials. Unilosa supplies them - Singapore-based.

📩 [email protected] 🌐 www.unilosa.com 📍 Singapore 🇸🇬

References: U.S. FDA, EMA, American Chemistry Council, official pharmaceutical company reports, and peer-reviewed scientific publications.

18/07/2026

🧬 Thousands of genetic diseases. Zero treatments. That is changing - right now in 2025 and 2026.

ZILGANERSEN (FDA review 2026 - Ionis): Alexander disease - fatal GFAP gene mutation causing toxic brain protein buildup. ZERO treatments exist. A*O drug targets the genetic root - reduces GFAP protein directly.

TRYNGOLZA (FDA approved 2024 - Ionis): First-ever treatment for Familial Chylomicronemia Syndrome - genetic inability to break down fats. Generated approximately $108 million in 2025 net sales. Proves RNA medicine works commercially.

IN VIVO GENE THERAPY: FDA approved approximately 9 gene therapy products in 2024. New 2026 frameworks accelerating approvals further. Off-the-shelf gene therapies - no patient cell extraction needed.

CRISPR BASE EDITING: Phase 2/3 trials for sickle cell and beta-thalassemia. Corrects ONE DNA letter. Potential permanent cures for single-mutation genetic diseases.

Manufacturing all of these requires the highest-purity pharma-grade chemicals in existence. Unilosa supplies them - Singapore-based.

📩 [email protected] 🌐 www.unilosa.com 📍 Singapore 🇸🇬

References: U.S. FDA, FDA Center for Biologics Evaluation and Research (CBER), Ionis Pharmaceuticals, and published clinical research.

13/07/2026

🔬 Approximately 10 targeted cancer therapies approved by FDA in 2025 alone. The era of precision oncology is here.

ZONGERTINIB - HER2-mutant lung cancer. Approved 2025, expanded to newly diagnosed patients Q1 2026. Targets the exact genetic mutation - not general chemotherapy.

ZENOCUTUZUMAB (Bizengri) - Rare bile duct cancer with NRG1 gene fusion. World's first bispecific antibody hitting both HER2 and HER3 simultaneously. FDA approved Q2 2026.

ENCORAFENIB TRIPLE COMBO - First-line colorectal cancer with BRAF V600E mutation. Triple combination approved Q1 2026. Target the genetic driver from day one.

KLN-1010 GENE THERAPY - Multiple myeloma. Off-the-shelf in vivo gene therapy. No patient cell extraction needed. FDA IND cleared January 2026.

The shift: 'treat all cancers the same' is ending. 'Target the exact genetic mutation' is beginning.

Every targeted therapy starts with pharma-grade synthesis chemicals. Unilosa supplies them - Singapore-based.

📩 [email protected] 🌐 www.unilosa.com 📍 Singapore 🇸🇬

References: U.S. FDA Drug Approvals, FDA Oncology Approval Notifications, and official pharmaceutical company announcements.

09/07/2026

💊 The obesity drug revolution is happening right now - and it is bigger than anything pharma has seen before.

December 2025: FDA approved the world's FIRST oral GLP-1 drug - Wegovy pill. Approximately $149/month. No injection needed.

April 1, 2026: Eli Lilly's Orforglipron (Foundayo) FDA approved - first GLP-1 tablet with ZERO food or water restrictions. Any time of day.

Still in FDA review 2026: CagriSema - GLP-1 + amylin combination. Approximately 23% body weight reduction in Phase 3 (NEJM, June 2025).

On the horizon post-2028: Retatrutide - TRIPLE action GLP-1 + GIP + GCG. Expected to exceed all current therapies in weight loss delivered.

Global obesity drug market: approximately $100 billion target. Eli Lilly crossed $1 trillion market cap - driven by obesity drugs.

Every one of these medicines starts with pharma-grade chemical raw materials. At Unilosa Chemicals, we supply them - all grades, verified origins, Singapore-based.

📩 [email protected] 🌐 www.unilosa.com 📍 Singapore 🇸🇬

04/07/2026

🔋 Most people think EV batteries run on cobalt and nickel. The fastest-growing battery chemistry in 2026 uses neither.

It is called LMF - Lithium Manganese Iron Phosphate.
WHAT IS LMFP?

LMFP builds on LFP by adding manganese, raising voltage from approximately 3.2V to approximately 3.7-3.9V. Result:

Approximately 15-20% more energy density than LFP - with NO cobalt, NO nickel, same excellent safety.

WHY MANGANESE IS THE FUTURE:

🔴 No cobalt = no DRC dependency, no ethics supply risk
🟠 CATL M3P: approximately 65% Mn content, approximately 15% cheaper than NMC

🚗 BYD Seal U: approximately 600 km range achieved with LMFP

📊 McKinsey: L(M)FP could reach approximately 44% global battery market share by 2025

🚀 Approximately 8 of top 10 auto groups launching LMFP
vehicles by 2026

MARKET NUMBERS (Verified Market Research, June 2026):

📈 Market value 2025: approximately $3.60 billion
📈 Projected value 2033: approximately $12.10 billion
📈 CAGR: approximately 16.3%

🌏 Asia Pacific market share: approximately 73%

SHIPMENT GROWTH:

Approximately 13,000 tonnes in 2024 → approximately 35,000 tonnes in 2025 → over 1.3 million tonnes forecast by 2030
At Unilosa Chemicals, we supply MnSO₄, MnO₂, Li₂CO₃ and LiOH - all in stock. Singapore-based.

📩 [email protected]
🌐 www.unilosa.com
📍 Singapore 🇸🇬

29/06/2026

🌍 June 2026 - 5 chemical industry stories reshaping global supply chains right now.

🔴 EUROPE HOLLOWING OUT - Approximately 8 million tonnes of new polyethylene capacity from China & US in 2026. European chemical complexes shutting down. McKinsey: approximately 3 years of consecutive demand decline. Supply chain 'middle' disappearing.

🟠 CHINA CHEMICALS LAW (May 2026) - Stricter CoA, MSDS & regulatory requirements now mandatory for all Chinese chemical exports. Approximately 60% of global supply chains affected. Non-compliant shipments = port delays & seizure.

🔵 AI DATA CENTERS - New chemical demand driver most teams haven't priced in. Cooling materials, solvents, ultra-pure gases, semiconductor chemicals. Global industrial production: approximately +2.2% in 2026, approximately +3.2% in 2027.

🟢 GREAT DIVERGENCE - Chemical industry splitting in two. Commodity players vs. specialty platforms. Specialty chemicals = significantly lower volatility. Approximately 44% of shortage drugs rely on a single country for one key material.

🟣 PHARMA RISK - Approximately 44% of shortage drugs at single-source risk. Approximately 80% of world ports on legacy logistics systems. Multi-origin Singapore-based distributors gaining strategic importance.

At Unilosa Chemicals, we track these shifts daily - so our clients stay ahead.

📩 [email protected] 🌐 www.unilosa.com 📍 Singapore 🇸🇬

Address

Singapore
049422

Telephone

+84913191396

Website

http://unilosa.com/

Alerts

Be the first to know and let us send you an email when Hóa chất Unilosa - Việt Nam posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Want your business to be the top-listed Engineering Company in Singapore?